• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Emerald Health Shares Data of Patented Cannabinoid Against Parkinson’s Disease

    Bryan Mc Govern
    Feb. 07, 2018 08:43AM PST
    Cannabis Investing News

    A division of Emerald Health Therapeutics announced key members of its scientific team found the potential for EHP-102 to treat Parkinson’s disease.

    Emerald Health Pharmaceuticals, a division of Emerald Health Therapeutics (TSXV:EMH), announced key members of its scientific team found the potential for EHP-102, a patented aminoquinone derivative of the non-psychoactive phytocannabinoid, to treat Parkinson’s disease.

    As quoted in the press release:

    This research was done in collaboration with Professor Javier Fernandez-Ruiz (University Complutense of Madrid, Spain).

    These results were published in the Journal of Neuroinflammation in a scientific paper entitled, “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor.” Co-authors of this paper included Eduardo Muñoz, MD, PhD, EHP’s Chief Scientific Officer and Mari-Luz Bellido, PhD, EHP’s Vice President of European Operations.

    Researchers evaluated the anti-inflammatory and neuroprotective properties of EHP-102 in two animal models of Parkinson’s disease, as well as in vitro cellular models. Findings showed that EHP-102 is neuroprotective against inflammation-driven neuronal damage in these models. EHP-102 is a peroxisome proliferator-activated receptor-γ (PPARγ) modulator acting on both the canonical and alternative binding sites. These data demonstrate that EHP-102 could potentially be used as a neuroprotective agent in Parkinson’s disease due to its multi-target properties specific to the disease.

    Click here to read the full press release.

    in vitrocannabis investingchief scientific officer
    The Conversation (0)

    Go Deeper

    AI Powered
    Biotech therapy capsule containing DNA strand surrounded by cells.

    Top 5 Canadian Biotech Stocks of 2025

    Emyria Limited

    Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×